Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06824155 | HEAT Trial (HER2 Antibody Therapy With Lutetium-177)(RAD202) | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07793500 | YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) | recruiting | Early Phase 1 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 28, 2026 |
| clinicaltrials |
| NCT07595237 | A IIT Study of 177Lu-DOTA-SNA040 | recruiting | Early Phase 1 | 12 | SmartNuclide BiopharmaINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05733949 | Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors | recruiting | Early Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06184321 | Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | recruiting | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04967833 | A Study of GC101 TIL in Advanced Solid Tumors (TR) | recruiting | Early Phase 1 | 20 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05087745 | A Clinical Study on TIL for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07680582 | An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors | recruiting | Early Phase 1 | 60 | Ruijin HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07556653 | Allogeneic WTX-212C in Advanced Solid Tumors(WTX-212C-IIT) | recruiting | Early Phase 1 | 24 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06400485 | AMT-676 in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | Multitude Therapeutics Inc.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | recruiting | Early Phase 1 | 10 | National Cancer Institute, NaplesOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07220447 | L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance | recruiting | Early Phase 1 | 50 | City of Hope Medical CenterOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05645523 | Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors | recruiting | Early Phase 1 | 25 | St. Jude Children's Research HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07561437 | NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors | recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07505069 | Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors | recruiting | Early Phase 1 | 10 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07487597 | Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07475182 | Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07414316 | A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. | recruiting | Early Phase 1 | 10 | Beijing Geekgene Technology Co., LTDINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07327632 | This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors | recruiting | Early Phase 1 | 300 | Innovent Biologics Technology Limited (Shanghai R&D Center)INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07242417 | TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | recruiting | Early Phase 1 | 30 | Beijing GoBroad HospitalOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07349160 | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06488950 | A Study of TIL in Advanced Solid Tumors (DFGD) | recruiting | Early Phase 1 | 30 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06328686 | Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases | recruiting | Early Phase 1 | 10 | Emory UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07106814 | Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06822998 | HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors(HF50) | recruiting | Early Phase 1 | 10 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06497010 | An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment | recruiting | Early Phase 1 | 40 | The Affiliated Hospital Of Guizhou Medical UniversityOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05916248 | Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 34 | Ruijin HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06150365 | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06718946 | Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06697665 | An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06695689 | An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05141474 | Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors(NEXTGENTIL-ACT) | recruiting | Early Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06515626 | Genetically Modified T Cells Treating Malignant Tumors | recruiting | Early Phase 1 | 100 | Yi ZhangOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT05831033 | Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05579275 | Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors | recruiting | Early Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06327997 | An Exploratory Study by Fast CAR T Cells | recruiting | Early Phase 1 | 20 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06248697 | Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249256 | An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05811975 | KSX01-TCRT Injection Project in Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05539833 | KSH01-TCRT Solid Tumors(KSH01-TCRT) | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05580796 | KSH01-R02-101 Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05166070 | An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors | recruiting | Early Phase 1 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02446431 | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence(Metronomic) | recruiting | Early Phase 1 | 20 | Miller Children's & Women's Hospital Long BeachOTHER | 1 | May 18, 2015 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials